← CASI Pharmaceuticals, Inc. (CASIF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CASI Pharmaceuticals, Inc. (CASIF)
Pharmaceutical Preparations · market cap $2M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
11
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Sunitinib Malate | Phase 2 | Metastatic Renal Cell Carcinoma |
| recombinant human Angiostatin protein | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| Panzem NCD | Phase 2 | Recurrent Glioblastoma Multiforme |
| Panzem Nanocrystal Colloidal Dispersion | Phase 2 | Recurrent Glioblastoma Multiforme |
| ENMD-2076 | Phase 2 | Advanced Adult Hepatocellular Carcinoma |
| MKC-1 | Phase 2 | Pancreatic Cancer |
| Panzem Nanocrystal Colloidal Dispersion (NCD) | Phase 2 | Ovarian Cancer |
| Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) | Phase 2 | Carcinoid Tumor |
| 2-methoxyestradiol | Phase 2 | Relapsed Multiple Myeloma |
| Panzem® NCD | Phase 2 | Prostate Cancer |
| CID-103 | Phase 2 | Antibody Mediated Rejection |
Price & technical context
3-month
-23.1%
6-month
-41.2%
12-month
-94.3%
52-wk range
$0.10–$1.78
vs 50-day MA
-21.5%
vs 200-day MA
-64.1%
Realized vol
224.2%
Max drawdown
-98.5%
Daily closes through 2026-10-20. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CASIF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.